Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Biotek-snakken
  4. Biotek-snakken — Oktober 2020

Biotek-snakken — Oktober 2020

Planlagt Fastgjort Låst Flyttet Biotek-snakken
260 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • B Offline
    B Offline
    BioShare
    wrote on sidst redigeret af
    #100

    Synes heldigvis der er ret god disciplin på dette site – og virkelig fedt at vi kan dele informationer om mulige små vindere her og der. Genmab-chatten har i mange år været et fantastisk eksempel på dette. Synes også der bliver delt meget god information her i Biotek-snakken….lad os endelig fortsætte med det!

    1 Reply Last reply
    0
    • B Offline
      B Offline
      BioShare
      wrote on sidst redigeret af
      #101

      Med hensyn til Iterum var det jo en joker (er fortsat). Synes en kurs under 1,00 har en pæn upside, og reaktionen efter udmelding om positivt FDA-møde (uagtet at Sulopenem nu KUN køres frem i uncomplicated urinary tract infections med quinolone-resistance, hvor salgspotentialet er betydeligt mindre) var at aktien handlede kortvarigt op i kurs 2,40 fra niveauet 0,62. Den er siden banket ned igen, og handlede i går 0,89.

      1 Reply Last reply
      0
      • B Offline
        B Offline
        BioShare
        wrote on sidst redigeret af
        #102

        Synes det lignede at missed endpoint fra fase 3 forsøgene var teknisk knockout – der er effekt og god safety, og der er reelt brug for produktet. Vi må se hvad der sker i aktien - i bagklogskabens lys skulle jeg have solgt alt over 2....og købt igen under 1. Det havde været sund fornuft 😉

        1 Reply Last reply
        0
        • L Offline
          L Offline
          lahn1
          wrote on sidst redigeret af
          #103

          🙂 Bioshare - ja Biotek er fyldt med overraskelser, gode og dårlige. Jeg er løbet tør for penge til jokere pt. så må vente med at kigge på Iterum til en anden gang. Vil se lidt på antibiotics til den lang portfolio

          1 Reply Last reply
          0
          • B Offline
            B Offline
            BioShare
            wrote on sidst redigeret af
            #104

            Lyder fornuftigt....lad høre om du finder andet interessant 🙂 Jeg har for nylig taget en portion Deinove SA (handler i EUR) som er et mix mellem antibiotics og bioactives. Deres vigtigste projekt er i fase 2 (DNV3837) som er under fast track (men også forsinket af covid). Studie kører i US. http://www.deinove.com/en/investor-room/documentation-center/investors-slide-deck

            1 Reply Last reply
            0
            • B Offline
              B Offline
              BioShare
              wrote on sidst redigeret af
              #105

              Dette link giver et billede af hvad der er i gang af udvikling i antibiotics - muligt at filtrere på (ikke alt er noteret desværre) https://www.pewtrusts.org/en/research-and-analysis/data-visualizations/2014/antibiotics-currently-in-clinical-development.

              1 Reply Last reply
              0
              • B Offline
                B Offline
                bb
                wrote on sidst redigeret af
                #106

                OCUL stiger med ca. 20% på foreløbige bedre end forventet salgstal for q3 2020 🙂

                1 Reply Last reply
                0
                • B Offline
                  B Offline
                  bb
                  wrote on sidst redigeret af
                  #107

                  KURA vil præsentere foreløbige data på fase 1 forsøget med Menin Inhibitor KO-539 på ASH d. 5 december. KURA stiger med ca. 7% til kurs 33,5 (ny ATH)

                  1 Reply Last reply
                  0
                  • F Offline
                    F Offline
                    Fandel
                    wrote on sidst redigeret af
                    #108

                    God morgen...

                    1 Reply Last reply
                    0
                    • B Offline
                      B Offline
                      Bisseministeren
                      wrote on sidst redigeret af
                      #109

                      Nogen der ved hvornår handlen med curasight åbner? Den kommer på børsen i dag, men kan ikke se den på nordnet 🙂

                      1 Reply Last reply
                      0
                      • L Offline
                        L Offline
                        lahn1
                        wrote on sidst redigeret af
                        #110

                        Tak for link BS

                        1 Reply Last reply
                        0
                        • Helge_LarsenPI-redaktørH Offline
                          Helge_LarsenPI-redaktørH Offline
                          Helge_LarsenPI-redaktør
                          wrote on sidst redigeret af
                          #111

                          For biotektosser: https://www.proinvestor.com/boards/87389/For-biotektosser

                          1 Reply Last reply
                          0
                          • Helge_LarsenPI-redaktørH Offline
                            Helge_LarsenPI-redaktørH Offline
                            Helge_LarsenPI-redaktør
                            wrote on sidst redigeret af
                            #112

                            Cantargia - Tumor shrinkage in NSCLC combination

                            6 of 9 evaluable patients with metastatic NSCLC showed objective response incl 1 compl response

                            The complete response has lasted more than 1 year

                            Video clip :https://twitter.com/RS6HK605/status/1314109285958324225

                            1 Reply Last reply
                            0
                            • F Offline
                              F Offline
                              Fandel
                              wrote on sidst redigeret af
                              #113

                              Cantargia. Det er meget positivt Helge...

                              1 Reply Last reply
                              0
                              • DarvinD Offline
                                DarvinD Offline
                                Darvin
                                wrote on sidst redigeret af
                                #114

                                Også interessant at BergenBio har indledt forsøg i kombi med Keytruda

                                1 Reply Last reply
                                0
                                • R Offline
                                  R Offline
                                  Rasbom
                                  wrote on sidst redigeret af
                                  #115

                                  Cantargia: endnu en god nyhed fra Cantargia. De har
                                  været gavmilde overfor aktionærerne den sidste måned.

                                  1 Reply Last reply
                                  0
                                  • K Offline
                                    K Offline
                                    Kaizers
                                    wrote on sidst redigeret af
                                    #116

                                    ArcticZymes has entered into an agreement with Simcere Diagnostics to supply its HL-SAN product for Simcere’s metagenomics sequencing tests

                                    Tromsø, 08 October, 2020: ArcticZymes AS, a subsidiary of ArcticZymes Technologies ASA (OSE:AZT), announces that it has entered into a supply and distribution agreement with precision medicine company Jiangsu Simcere Diagnostics, Nanjing, China for the supply of Heat-Labile Salt Active Nuclease (HL-SAN) to be used in the development and manufacturing

                                    1 Reply Last reply
                                    0
                                    • K Offline
                                      K Offline
                                      Kaizers
                                      wrote on sidst redigeret af
                                      #117

                                      ArcticZymes Technologies ASA, CEO, Jethro Holter said: “We look forward to supporting Simcere in the development and future commercialization of their innovative sequencing assays as well as other future technologies. This is just the beginning of a long-term relationship together where ArcticZymes’ novel enzyme technologies and scientific competence will aid Simcere Diagnostics in marketing best in class sequencing technologies. The agreement marks the first step for ArcticZymes in China.

                                      1 Reply Last reply
                                      0
                                      • K Offline
                                        K Offline
                                        Kaizers
                                        wrote on sidst redigeret af
                                        #118

                                        Simcere Diagnostics CEO, Yong Ren said:
                                        “Simcere Diagnostics is excited to collaborate with ArcticZymes AS. This global collaboration not only helps Simcere in the development and commercialization of its metagenomic products, it also provides our friend ArcticZymes with a market penetration opportunity to the Chinese market. We plan to work closely in the future to explore additional means to strengthen our partnership and achieve additional penetration in China.”

                                        1 Reply Last reply
                                        0
                                        • K Offline
                                          K Offline
                                          Kaizers
                                          wrote on sidst redigeret af
                                          #119

                                          HL-SAN is a critical component of Simcere Diagnostics’ infectious disease metagenomic assays. In particular, the nuclease supplied by ArcticZymes plays a key role in the removal of host DNA from the sample. This results in a streamlined and efficient sample preparation process that reduces background noise from the assay. Metagenomic assays are extremely sensitive to competing background noise. Fortunately, HL-SAN’s unique capability to interact with salt provides Simcere the best host DNA remov

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper